Pirfenidone can regulate the ROS-dependent NLRP3-IL-1β signaling pathway by inhibiting NLRP3, improving left ventricular hypertrophy and myocardial fibrosis in rats with TAC (93). This evidence concerns the gene NLRP3 and persistent truncus arteriosus.